The global Oncology Blood Testing Market is poised for exceptional growth, projected to surge from USD 5.9 billion in 2025 to USD 24.2 billion by 2035, reflecting a robust compound annual growth rate (CAGR) of 15.2%, according to a new industry forecast. This momentum is being fueled by rising cancer incidence, expanding adoption of liquid biopsy assays, and advancements in molecular diagnostics that are transforming cancer care.
Industry Shift Toward Minimally Invasive Cancer Diagnostics
The market’s trajectory is underpinned by the healthcare sector’s growing reliance on non-invasive blood-based cancer detection methods. In 2025, liquid biopsy assays are expected to dominate the market with a 31.6% share, leveraging their ability to detect tumor-specific biomarkers from a simple blood draw. These tests are increasingly preferred over traditional tissue biopsies for their speed, safety, and capacity to guide personalized medicine strategies.
Lung cancer will remain the leading application, representing 29.4% of total market revenue in 2025. Early detection tools, particularly those identifying actionable genetic mutations, are enabling targeted therapies and improving survival rates. Hospitals will account for 45.8% of market revenue, reflecting their central role in diagnosis, treatment planning, and ongoing monitoring.
Click Here for More Information:- https://www.futuremarketinsights.com/reports/oncology-blood-testing-market
Regional Growth and Market Dynamics
North America will lead the market with a commanding 52.6% share in 2025, driven by favorable reimbursement frameworks, advanced diagnostic infrastructure, and growing awareness of early detection. Europe follows closely, benefiting from streamlined regulatory approval pathways for in-vitro cancer diagnostics. Meanwhile, the Asia-Pacific region is set for accelerated growth due to increasing cancer prevalence, rising research investments, and expanding diagnostic capabilities.
Globally, the market is benefiting from precision medicine initiatives, enhanced next-generation sequencing (NGS) capabilities, and public-private collaborations that are making oncology blood testing more accessible and clinically impactful.
Competitive Benchmarking and Innovation Trends
Key players such as Guardant Health Inc., Roche, Foundation Medicine Inc., Genomic Health Inc., and Bio-Techne are investing heavily in assay sensitivity, multi-omics platforms, and real-time cancer monitoring technologies. Startups like Grail, Freenome, and Adaptive Biotechnologies are challenging incumbents with innovative circulating tumor DNA (ctDNA) and circulating tumor cell (CTC) platforms, expanding test utility beyond diagnosis to treatment optimization and recurrence monitoring.
Notable recent developments include:
- Burning Rock Biotech (May 2024) launching China’s first blood-based pan-cancer study using a multi-omics approach.
- Biofidelity Ltd. (July 2024) opening a North Carolina headquarters to scale next-gen oncology diagnostics.
- Academic collaborations such as Monash University’s myeloma detection assay and the Dana-Farber Cancer Institute’s high-risk multiple myeloma screening program.
Growth Drivers and Opportunities
Market expansion is fueled by:
- Increasing cancer incidence globally, with WHO reporting millions of new cases annually.
- Technological advancements in digital PCR, immunohistochemistry, NGS, and molecular pathology.
- Rising adoption of drug-diagnostic co-development models, aligning with the personalized medicine trend.
- Expanded reimbursement coverage for advanced molecular tests in key markets.
Opportunities for further growth lie in real-time cancer diagnostics, improved minimal residual disease monitoring, and expanded use of oncology blood testing in preventive care.
Challenges to Overcome
While the outlook is strong, market growth faces hurdles such as high molecular diagnostic costs, uneven access to advanced testing in developing regions, and reimbursement uncertainties outside North America and Europe. Overcoming these challenges will require cost-reduction innovations, capacity building in emerging economies, and streamlined regulatory pathways.
Outlook to 2035
With the oncology blood testing market set to more than quadruple in size over the next decade, industry stakeholders are positioned for significant gains. As diagnostic accuracy improves and test accessibility widens, blood-based cancer detection will become a standard component of early diagnosis, treatment planning, and ongoing patient monitoring.
Get Sample Report: – https://www.futuremarketinsights.com/reports/sample/rep-gb-6449
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
